BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
GlobeNewsWire
Published: Aug 04, 2026, 10:45 AM
Sentiment Analysis
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three and six months ended June 30, 2026 and provided an update on its corporate progress.
“In the first half of 2026, we made important progress in turning our mission into reality. We significantly advanced our late-stage oncology pipeline, with six pivotal trials initiated; we pioneered the generation of first-in-class global Phase 2 data for an investigational PD-L1xVEGF bispecific antibody in first-line non-small cell lung cancer across PD-L1 expression levels and histologies; and we demonstrated at medical congresses that our novel-novel combination therapy strategy is gaining momentum,” said Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech . “We look forward to welcoming BioNTech's next CEO. Guido Oelkers will take office by February 1, 2027, at the latest, and, together with the Management Board and teams across the company, is expected to continue to write the BioNTech success story.”
Financial Review for Second Quarter and First Half of 2026 in millions €, except per share data
Second Quarter 2026 Second Quarter 2025 IFRS Results Adjusted Results 2 IFRS Results Adjusted Results 2 Revenues 105.6 105.6 260.8 260.8 Net loss (820.8) (562.3) (386.6) (348.8) Diluted loss per share (3.24) (2.22) (1.60) (1.45)
in millions €, except per share data Year-to-date 2026 Year-to-date 2025 IFRS Results Adjusted Results 2 IFRS Results Adjusted Results 2 Revenues 223.7 223.7 443.6 443.6 Net loss (1,352.7) (1,056.9) (802.4) (779.6) Diluted loss per share (5.34) (4.17) (3.33) (3.23)
Below figures compare the second quarter of 2026 and the year-to-date period ended June 30, 2026, to the corresponding prior year periods, except as noted. Revenues were €105.6 million for the second quarter of 2026, compared to €260.8 million. Year-to-date revenues were €223.7 million, compared to €443.6 million. The decreases in both quarterly and year-to-date revenues compared to the prior year were primarily driven by lower demand from BioNTech’s COVID-19 vaccines.
Source: GlobeNewsWire
This content is not intended as investment advice or a recommendation. Any opinions expressed are solely the personal views of each article.